Luminex Corporation Receives FDA Clearance and CE-IVD Mark for the ARIES M1 System

The ARIES M1 System is designed to empower satellite clinical laboratories to take advantage of the same benefits as Luminex's higher throughput ARIES System, with features such as an intuitive system interface, STAT or batch testing, and true walkaway capability. The system extracts, amplifies and detects nucleic acid targets from a variety of sample types. Once the cassettes are loaded onto the instrument, results are generated without additional technical intervention. The system can process up to six different samples, and one to six assays, at a time.

"In developing the ARIES family of systems, we listened closely to the needs of our customers and crafted these products to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today's lean laboratory. We are now adding another system based on customer feedback, and in doing so, expanding our market reach," said Homi Shamir, President and Chief Executive Officer of Luminex. "Luminex now has the broadest offering of low-plex and high-plex sample to answer systems for clinical laboratories performing molecular diagnostic testing. And, with the acquisition of NSPH behind us, we can focus on continuing to move products in our pipeline towards commercialization and realizing the value in our newly acquired asset."

The new system will be on display at the upcoming AACC Annual Scientific Meeting & Clinical Lab Expo which is happening July 31–August 4 in Philadelphia, PA.

Learn more or request a demo, visit: www.luminexcorp.com/ARIES 

About the ARIES^® Systems
The ARIES^® Systems are sample to answer molecular diagnostic platforms designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today's lean laboratory environment. ARIES^® uses internal barcode scanning and other advanced features to minimize operator errors. An integrated touchscreen PC eliminates the need for a separate computer, standalone keyboard, and mouse, maximizing valuable bench space. The low throughput ARIES^® M1 System provides one module with the ability to run one to six different assays according to the ARIES^® Universal Assay Protocol. The higher throughput ARIES^® System provides two independent modules, each which support from one to six cassettes, allowing for both STAT and Batch testing of IVD and homebrew assays using MultiCode^® Reagents when using a universal assay protocol.

About Luminex Corporation
Luminex is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP^® open-architecture multi-analyte platform, MultiCode^® real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, biotechnology and life science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com/.

Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding the available market for ARIES^®, future revenue growth anticipated for ARIES^®, and the development, testing and regulatory approval progress of our pipeline products, including ARIES^® related assays. The words "believe", "expect", "intend", "anticipates", "confident", "will", "could", "should",  and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, our ability to launch products on time, the timing of regulatory approvals, the outcome of clinical trials as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contacts: 

Luminex Investor Contact 
Harriss Currie, 512.219.8020 
Sr. Vice President of Finance and CFO 
hcurrie@luminexcorp.com

Luminex Media Contact 
Christine Valle, 512.219.8020
Sr. Manager, Global Marketing
cvalle@luminexcorp.com

Related Links

http://www.luminexcorp.com